SCHEMBL6154491

SCHEMBL6154491

COc1cc(NC2CCSCC2)ccc1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.47
FLT3 P36888 1/20 0.47
PARP15 Q460N3 1/20 0.44
PARP10 Q53GL7 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
SYK P43405 3/20 0.39
MAPT P10636 1/20 0.39
GAA P10253 2/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
PDE7A Q13946 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154287 0.87 PARP15 (0.55) KITFLT3PARP15PARP10SYK
SCHEMBL6153579 0.86 KIT (0.60) KITFLT3PARP15PARP10MEN1
SCHEMBL6153341 0.86 KIT (0.60) KITFLT3PARP15PARP10MEN1
SCHEMBL6153345 0.86 KIT (0.60) KITFLT3PARP15PARP10MEN1
SCHEMBL6153679 0.85 HTR4 (0.48) KITFLT3PARP15PARP10MEN1
SCHEMBL6153322 0.85 FLT3 (0.47) KITFLT3PARP15PARP10MEN1
SCHEMBL6154425 0.84 EHMT2 (0.50) KITFLT3PARP15PARP10MAPT
SCHEMBL6154256 0.82 PARP15 (0.48) KITFLT3PARP15PARP10MEN1
SCHEMBL6154278 0.82 PARP15 (0.48) KITFLT3PARP15PARP10MEN1
SCHEMBL6154337 0.81 MAPT (0.52) KITFLT3LMNASYKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 KIT 775/4885FLT3 2536/4885PARP15 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.